Introduction
============

Cancer has been regarded as one of the most frequent causes of death in economically developing and developed countries. According to the 2018 updated global estimation, there are approximately 42 million people across the world suffered from any type of cancer. Including 8 million had breast cancer, 6.3 million had colon and rectum cancer, 5.7 million with prostate cancer and over 2.8 million suffered from respiratory cancer[@B1]. Another worldwide result conducted by GLOBOCAN represented that there are about 12.7 million new cancer cases and 7.6 million deaths had occurred in 2012, suggested that cancer has become a primary public health threat[@B2]. It is established that cancers were multifactorial diseases which commonly arose from these intricate interactions between genetic and environmental factors[@B3].

For the past few years, numerous epidemiologic studies have uncovered that single nucleotide polymorphisms (SNPs) in the cytokine family may contribute to the tumorigenesis of many cancers in several ways, such as, influencing the function of cytokines participated in immune reactions and inflammatory responses, affecting the binding of nuclear factors with targeted genes, and inhibiting apoptosis [@B4]. Interleukin-4 (IL-4) is a member of the α-helical cytokine family, which is generated by activated CD4+T cells, basophils, and mast cells, regarding as the central differentiation factor managing Th2 development, removing extracellular pathogens, and inhibiting Th1 differentiation. In addition, IL-4 receptor (IL-4R) is a heterodimeric complex that can bind to the Th2 cytokines IL-4 and IL-13[@B5], [@B6]. Overexpression of IL-4R has been observed in colorectal carcinoma [@B6]. In addition, polymorphisms in IL-4R were identified implicated in the tumorigenesis of a variety of cancer types, including pancreatic cancer, renal cell carcinoma, bladder cancer and cervical cancer [@B7]-[@B10]. For example, Schwartzbaum *et al.* reported an increased susceptibility of glioblastoma contributed by rs1801275 of IL-4R [@B11], however, Li *et al.* indicated that the mutant G allele plays a protective function in tumorigenesis [@B12]. The inconsistent might cause by the differences of genotyping methods, source of control, and ethnic lines, as well as the small-scale sample size. Therefore, we conducted a comprehendsive meta-analysis to explore the association between IL-4R polymorphisms and cancer susceptibility.

Material and Methods
====================

Literature search
-----------------

All eligible publications up to May 25, 2018 were retrieved and extracted by investigators from the databases of PubMed, Google Scholar, Web of Science, CNKI and Wanfang databases, respectively. When discrepancies occurred in data interpretation, we will deal with them by discussing, review of the publications, and counseling other cancer research experts if necessary. The keywords applied for literature retrieve are as follows: ("IL-4R," OR "Interleukin-4 receptor," OR "IL4R,") AND ("SNP," OR "mutation," OR "variant," OR "polymorphism,") AND ("cancer," OR "carcinoma," OR "tumor," OR "malignancy," OR "leukemia" OR "lymphoma"). In addition, we conducted a manual retrieve for the additional eligible studies from the studies cited in the reference lists.

Inclusion criteria and exclusion criteria
-----------------------------------------

The publications enrolled in our studies should keep to the following inclusion criteria: 1) publications should illustrate the association between the polymorphisms in IL-4R and cancer susceptibility; 2) The detail genotype frequency of the cases and controls could be obtained directly or indirectly through calculating; 3) case-control studies. However, publications should be removed when they were: 1) no control studies, meta-analysis or systematic review, comments, and case report; 2) no efficient data of the genotype frequency offered; 3) repetitive publications; 4) the publications were conducted on animals or cell lines; 5) they were concerned about other disorders instead of cancers.

Data extraction
---------------

Two investigators extracted data from the enrolled case-control studies individually. The following details were collected from each study: the name of the first author, the date of publication, ethnicity, sample size, genotyping method, and genotype frequency of the cases and controls. By comparing enrolled forms between two investigators, the accuracy of the data was verified. If any difference was generated, we would check the full-text of the articles.

Statistical analysis
--------------------

We applied ORs with corresponding 95% CIs to assess the strength of the relationship between the polymorphisms in IL-4R and overall cancer susceptibility. Five common genetic models applied for assessing gene-disease associations are allele contrast model (B vs. A), heterozygote model (BA vs. AA), homozygote model (BB vs. AA), recessive model (BB vs. BA+AA) and dominant model (BA+BB vs. AA) (AA, homozygotes for the wild allele; AB, heterozygotes; BB, homozygotes for the mutant allele). Bonferroni corrections were also performed to adjust the results, *P~adjust~* = 0.05\* number of calculated polymorphism \* 5 models, and less than 0.05 was considered as statistically significant[@B13]. In addition, we applied the chi-squared (χ2)-based Q test to calculate between-study heterogeneity[@B14]. P\<0.1 was indicated a substantial level of heterogeneity, and a random effects model (the DerSimonian and Laird method) was selected to pool the data [@B15]; or else, the fixed effects model (the Mantel-Haenszel method) was adopted. Stratified analyses were also calculated by ethnicity, cancer type, the genotyping method and the source of control. Moreover, we also conducted the Begg\'s funnel plots and Egger\'s test to evaluate the publication bias [@B16], [@B17]. Hardy-Weinberg equilibrium (HWE) of controls was calculated by the χ2 test. We applied STATA 12.0 (Version 12.0, Stata Corp) to conduct all the statistical analyses, and all the *P* values were two-sided.

Linkage Disequilibrium (LD) Analysis and *in-silico* analysis of IL-4R expression
---------------------------------------------------------------------------------

Data were extracted from the 1000 genomes project comprising the polymorphisms in genes of IL-4R in the current study. CHB (Han Chinese in Beijing, China), CHS (southern Han Chinese, China), CEU (Utah residents with Northern and Western European ancestry from the CEPH collection), JPT (Japanese in Tokyo, Japan) and YRI (Yoruba in Ibadan, Nigeria), ESN (Esan in Nigeria) were enrolled in the calculate project, analyses were performed with Haploview software, LD in each above-mentioned population was assessed by r^2^ statistics.

In order to further explore the relationship between IL-4R expression and cancer, we used a newly developed interactive web server, GEPIA (<http://gepia.cancer-pku.cn/>), which provided the RNA sequencing expression data of tumors and normal samples from the TCGA and the GTEx projects[@B18].

Results
=======

Study characteristics
---------------------

A total of 31 publications including 53 case-control studies satisfied the inclusion criteria, including 24452 cancer patients and 24971 controls focused on rs1801275, rs1805010, rs1805015 and rs2057768, while another 5 polymorphisms (rs1805011, rs1805012, rs1805013, rs1805016, rs3024536) were finally exceeded because of less than 3 studies. We provide a flowchart to show the details of the data selection process (**Figure [1](#F1){ref-type="fig"}**). There were 26 case-control studies of the rs1801275 polymorphism[@B5], [@B8], [@B9], [@B11], [@B12], [@B19]-[@B37], 15 of the rs1805010 polymorphism[@B5], [@B9], [@B20], [@B23]-[@B26], [@B28], [@B32], [@B33], [@B37]-[@B40], 9 of the rs1805015 polymorphism[@B9], [@B11], [@B12], [@B23], [@B24], [@B32], [@B33], [@B38], [@B41], and 3 of the rs2057768 polymorphism[@B42]-[@B44]. 19 studies were performed in Asians, 29 in Caucasians, 2 in the mixed group (more than two descendant), and 1 in African group. The characteristics of each case-control study, genotype frequencies and HWE examination results were presented in **Table [1](#T1){ref-type="table"}**. Six case-control studies were not comforted to HWE[@B11], [@B24], [@B26], [@B34], [@B35], [@B40], and we further conducted a sensitive analysis to validate the influence of the three studies on the integrated data. In order to evaluate the quality of each enrolled studies, we applied Newcastle-Ottawa Scale (NOS) [@B45], and filled the result in **Table [S1](#SM0){ref-type="supplementary-material"}**, the result of PRISMA2009 checklist was also listed to present our meta-analysis work (**Table [S2](#SM0){ref-type="supplementary-material"}**).

Quantitative data synthesis
---------------------------

The summary of the meta-analysis between the IL-4R polymorphisms and cancer susceptibility was shown in **Table [2](#T2){ref-type="table"}**. After complicated calculation, we revealed that there is no significant association between rs1801275, rs1805010, rs1805015, and rs2057768 polymorphisms and cancer susceptibility in the overall population **(Figure [2](#F2){ref-type="fig"}, Figure [S1](#SM0){ref-type="supplementary-material"}-S3)**. In the subgroup analyses stratified by ethnicity, cancer type, the genotyping method or the source of control, the homozygote model of cervical cancer in rs1801275 shown a decreased risk (BB vs. AA: OR (95% CI) = 0.581(0.364-0.925), *P~H~*=0.022), while shown an increased risk in breast cancer (BB vs. AA: OR (95% CI) = 1.181(1.006-1.386), *P~H~*=0.043), the recessive model of cervical cancer in rs1801275 also shown a decreased risk (BB vs. BA+AA: OR (95% CI) = 0.59(0.374-0.931), *P~H~*=0.024). For rs1805010, several significant risk were shown in HB subgroup of heterozygote model (BA vs. AA: OR (95% CI) = 1.151(1.001-1.323), *P~H~*=0.049), HB subgroup of dominant model (BA+BB vs. AA: OR (95% CI) = 1.167(1.022- 1.332), *P~H~*=0.023), PCR subgroup of recessive model (BB vs. BA+ AA: OR (95% CI) = 0.767 (0.604- 0.974), *P~H~*=0.03), gastric cancer subgroup of recessive model (BB vs. BA+AA: OR (95% CI) = 0.785 (0.617-0.998), *P~H~*=0.048). For rs1805015, the significant risk was shown in Asian population subgroup of homozygote model (BB vs. AA: OR (95% CI) = 0.24(0.076- 0.752), *P~H~*=0.014), Asian population subgroup of recessive model (BB vs. BA+AA: OR (95% CI) = 0.239(0.076-0.749), *P~H~*=0.014). For rs2057768, the subgroup of PB and gastric cancer shown statistical difference in heterozygote model (BA vs. AA), recessive model (BB vs. BA+AA) or dominant model (BA+BB vs. AA). However, after Bonferroni corrections, all the *P~adjust~* value is higher than 0.05. The results revealed that there is no significant association between IL-4R polymorphisms and cancer risks in stratification analyses.

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analysis was applied to assess the impaction of the individual studies on the integrated data by removing a single data from the pooled analysis every time for each polymorphism. We uncovered that there was no individual study influenced the result of pooled ORs (**Figure [3](#F3){ref-type="fig"} and Table [S3](#SM0){ref-type="supplementary-material"}**). Furthermore, Begg\'s funnel plot and Egger\'s test was conducted to evaluate the publication bias, and no significant evidence of distinct asymmetry was disclosed through the shapes of the funnel plots, as well as the value of P \> \|t\| in Egger\'s test (**Figure [4](#F4){ref-type="fig"} and Table [S4](#SM0){ref-type="supplementary-material"}**).

LD Analyses across Populations and *in-silico* analysis of IL-4R expression
---------------------------------------------------------------------------

For better understanding the quantitative synthesis, LD analysis was performed to test the presence or absence of bins in the region containing these polymorphisms in IL-4R. LD plots for polymorphisms in IL-4R genes were presented in **Figure [S4](#SM0){ref-type="supplementary-material"}.** Highlighted, there is significant LD between rs1805010 and rs1801275 in CEU and JPT populations (CEU: r^2^= 0.7; JPT: r^2^= 0.67).

*In-silico* results indicated that the expression of IL-4R in colon adenocarcinoma was higher than that in normal colon tissue (Transcripts Per Kilo base Million (TPM) =41.6 vs. 60.0, P \< 0.01), as well as in rectum adenocarcinoma (TPM=43.6 vs. 58.4, P \< 0.01), kidney Chromophobe (TPM=6.47 vs. 21.8, P \< 0.01), kidney renal clear cell carcinoma (TPM=43.7 vs. 18.2, P \< 0.01), and pancreatic adenocarcinoma (TPM=62.4 vs. 4.99, P \< 0.01). All the result is shown in **Figure [S5](#SM0){ref-type="supplementary-material"}**.

Discussion
==========

At present, the identification of novel genetic and molecular predictors is desiderata, in order to successfully early diagnose or prevent the malignancies. Several biomarks are reported might be associated with tumorigenesis. IL4R, which encodes the alpha chain of the IL-4R, can bind IL-4 and IL-13 contributing to the regulation of IgE production[@B46], one soluble form of the encoded protein can restrain IL-4 mediated cell proliferation. Enormous genetic studies have uncovered that several SNPs in IL-4R gene were identified to be significantly associated with many diseases, including cancers [@B47]. These SNPs have the ability to regulate the efficacy of gene expressions, interfere with the synthesis of the protein, disrupt signaling pathways and result in the instabilities of the exonic mRNA [@B47], [@B48].

The recent study has suggested that rs1801275 polymorphism in the IL-4R gene can predict 2.29-fold glioblastoma susceptibility by the over-dominant model[@B34], a result consistent with a previous study that rs1801275 contributed to an increased susceptibility of glioblastoma (OR = 1.61, 95% CI, 1.05-2.47) in a population-based study[@B11]. However, Li *et al.* indicated that the mutant G allele plays a protective function in tumorigenesis (OR=0.71, 95%CI, 0.50-0.99) [@B12]. Moreover, a significantly increased susceptibility of gastric cancer was identified in the IL-4R rs1805010 polymorphism in a Caucasian population[@B26], which was not consistent with previous investigations that no association of SNPs in IL-4R gene and gastric cancer susceptibility were displayed in Taiwan \[20\]and Japanese[@B39] populations. And in a separate research, Chu *et al.* [@B9] identified that IL-4R rs1805010 polymorphism was associated with a significantly decreased susceptibility of renal cell carcinoma. A large number of case-control studies have elaborated the association between these polymorphisms in IL-4R and the susceptibility of a variety of cancer types, data from these publications remained inconsistent and controversial.

Meta-analysis is a validated method, by which we can enlarge the effective sample size via pooling the data from the separate related case-control studies. Besides, the statistical power for estimation of the genetic effects was also enhanced [@B49]. There are several previous meta-analyses also concerned about IL-4R and tumorigenesis. Cho *et al.*[@B50] demonstrated a reduced risk of GC for rs1801275, but they mixed the gastric cancer, esophageal cancer, pancreatic cancer and colorectal cancer, without any subgroup analysis of cancer type. Wang *et al.*[@B51] performed a meta-analysis about IL-4R and cancer risk on rs1801275, rs1805010 and rs1805015, however, they only enrolled 36 studies, and didn\'t adjust the P value of Q-test, which might lead to statistical error.

All in all, our recent updated meta-analysis draw a comprehensive, precise and convincible result, which is that rs1801275, rs1805010, rs1805015 and rs2057768 polymorphisms of IL-4R are not associated with tumorigenesis. The advantages of this research should not be buried. Firstly, a comprehensive search was conducted to identify more qualified studies, this analysis is persuasive and substantive. Secondly, the quality of each registered research was evaluated by NOS scale, low-quality studies were eliminated to raise the credibility of results. Thirdly, stratification analysis was performed by ethnicity, source of controls, tumor type or race, in order to decrease the impact of heterogeneity and obtain the real conclusion. Fourthly, Bonferroni corrections formula was used to adjust the results of polymorphism, ensuring avoid overstating results. Fifthly, sensitivity analysis was presented to confirm the stability of conclusion calculated from these studies, and Egger\'s test and Begg\'s funnel plot was carried out to detect publication bias. Nevertheless, there are still several limitations that should be mentioned. Firstly, we have enrolled some small size case-control studies that contained small-scale numbers of the cases and controls. Thus, an insufficient capacity that slight effects on cancer susceptibility occurred when a stratified analysis was conducted by the cancer type, ethnicity, source of control, genotyping method and etc. Secondly, the controls were not accordant defined, part of them was population-based and the others were hospital-based. Therefore, when the polymorphism was predicted to influence the susceptibility of other diseases, the controls may not invariably be represented in the potential source populations. Thirdly, the majority of the enrolled studies were Caucasian groups, and no African data were available. Fourth, since the lack of raw data, such as smoking and drinking status, we are unable to perform a further assessment for the potential gene-gene and gene-environment interactions.

In conclusion, our work suggested that no significant association was identified between IL-4R polymorphisms and cancer susceptibility. Further well-designed studies with large sample sizes will be continued on this issue of interest.
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IL-4R

:   Interleukin-4 receptor

IL-4

:   Interleukin-4

ORs

:   Odds ratios

CIs

:   Confidence intervals

SNP

:   Single nucleotide polymorphism

HWE

:   Hardy-Weinberg equilibrium

NOS

:   Newcastle-Ottawa Scale

LD

:   Linkage Disequilibrium

TPM

:   Transcripts Per Kilobase Million.

![Flow chart presenting the study selection procedure.](jcav10p1538g001){#F1}

![Meta-analysis of the association between IL-4R rs1801275 polymorphism and overall cancer risk.](jcav10p1538g002){#F2}

![**Begg\'s funnel plot for publication bias test under 4 polymorphisms of IL-4R gene (B vs. A).** The x-axis is log (OR), and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate.](jcav10p1538g003){#F3}

![**Sensitivity Analysis of Overall ORs Co-Efficients for 4 polymorphisms of Il-4R gene (B vs. A).** Results were calculated by omitting each study in turn. The two ends of the dotted lines represent the 95% CIs.](jcav10p1538g004){#F4}

###### 

Details of enrolled studies for current meta-analysis and systematic review

  SNP         First author                   Year   Ethnicity   Genotyping Method   Source of Control   Cancer Type   case   control                           
  ----------- ------------------------------ ------ ----------- ------------------- ------------------- ------------- ------ --------- ----- ----- ----- ----- ---
  rs1801275   Calhoun*et al.^19^*            2002   Caucasian   PCR                 PB                  CC            78     45        4     60    41    7     Y
  rs1801275   Nakamura *et al.^5^*           2002   Asian       PCR-RFLP            HB                  RC            98     40        5     161   42    2     Y
  rs1801275   Wu *et al.^20^*                2003   Asian       PCR                 HB                  GC            160    57        3     164   61    5     Y
  rs1801275   Schwartzbaum*et al.^11^*       2005   Caucasian   PCR-RFLP            PB                  HL            53     45        11    243   236   24    N
  rs1801275   Balasubramanian *et al.^21^*   2006   Caucasian   Taq-Man             PB                  BC            493    249       33    451   288   28    N
  rs1801275   Brenner *et al.^22^*           2007   Caucasian   PCR                 HB                  Glioma        407    214       28    651   331   44    Y
  rs1801275   Ivansson*et al.^23^*           2007   Caucasian   Taq-Man             PB                  CC            766    462       66    163   100   23    Y
  rs1801275   Landi *et al.^24^*             2007   Caucasian   Taq-Man             HB                  CRC           183    87        14    332   180   24    Y
  rs1801275   Olson *et al.^8^*              2007   Caucasian   PCR-RFLP            PB                  PC            104    38        7     89    41    5     Y
  rs1801275   Wiemels *et al.^38^*           2007   Caucasian   PCR-RFLP            PB                  Glioma        243    126       15    303   144   22    Y
  rs1801275   Gu*et al.^25^*                 2008   Caucasian   PCR                 PB                  Melanoma      120    64        11    121   65    7     Y
  rs1801275   Yang *et al.^27^*              2008   Mixed       PCR-RFLP            PB                  UBC           406    193       29    374   229   22    Y
  rs1801275   Zambon*et al.^26^*             2008   Caucasian   Taq-Man             HB                  GC            17     7         0     29    15    1     Y
  rs1801275   Lee*et al.^29^*                2010   Asian       PCR-SSP             HB                  CRC           137    29        4     84    43    4     Y
  rs1801275   Mohan *et al.^28^*             2009   Caucasian   PCR-RFLP            PB                  RC            37     9         4     31    17    3     Y
  rs1801275   Scola*et al.^30^*              2010   Caucasian   PCR-RFLP            HB                  PC            32     11        15    79    48    4     Y
  rs1801275   Chu *et al.^32^*               2012   Asian       Taq-Man             HB                  UBC           559    227       26    793   314   30    Y
  rs1801275   Ruan *et al.^31^*              2011   Asian       PCR                 HB                  Glioma        462    196       14    466   205   25    Y
  rs1801275   Chu *et al.^9^*                2012   Asian       Taq-Man             HB                  RC            407    195       18    424   176   23    Y
  rs1801275   Li*et al.^12^*                 2012   Asian       PCR                 PB                  Glioma        161    62        2     157   88    5     Y
  rs1801275   Ingram *et al.^33^*            2013   Mixed       Taq-Man             PB                  CRC           847    524       77    364   190   23    Y
  rs1801275   Jin *et al.^34^*               2013   Asian       PCR                 PB                  Glioma        56     14        2     187   105   6     N
  rs1801275   Quan *et al.^35^*              2014   Caucasian   PCR                 PB                  BC            642    288       47    660   261   32    Y
  rs1801275   Quan *et al.^35^*              2014   African     PCR                 PB                  BC            296    490       800   360   522   847   N
  rs1801275   Sousa*et al.^36^*              2015   Caucasian   Taq-Man             PB                  NPC           159    63        16    436   212   39    Y
  rs1801275   Liang *et al.^37^*             2017   Asian       PCR-LDR             HB                  RC            84     44        4     100   43    2     Y
  rs1805010   Nakamura*et al.^5^*            2002   Asian       PCR-RFLP            HB                  RC            42     76        25    84    94    27    Y
  rs1805010   Wu *et al.^20^*                2003   Asian       PCR                 HB                  GC            51     120       49    52    119   59    Y
  rs1805010   Ivansson *et al.^23^*          2007   Caucasian   Taq-Man             HB                  CC            365    653       267   99    147   38    Y
  rs1805010   Landi *et al.^24^*             2007   Caucasian   Taq-Man             HB                  CRC           83     141       55    162   262   102   Y
  rs1805010   Wiemels*et al.^38^*            2007   Caucasian   PCR-RFLP            HB                  Glioma        119    196       72    148   232   91    Y
  rs1805010   Gu *et al.^25^*                2008   Caucasian   PCR                 PB                  Melanoma      67     104       43    57    110   50    Y
  rs1805010   Zambon *et al.^26^*            2008   Caucasian   Taq-Man             HB                  GC            4      9         10    19    15    11    N
  rs1805010   Crusius *et al.^42^*           2008   Caucasian   PCR                 PB                  GC            71     134       39    352   549   249   Y
  rs1805010   Mohan *et al.^28^*             2009   Caucasian   PCR-RFLP            PB                  RC            20     12        18    23    22    6     Y
  rs1805010   Ando *et al.^39^*              2009   Asian       PCR-RFLP            HB                  GC            137    156       37    77    85    28    Y
  rs1805010   Chu*et al.^9^*                 2012   Asian       Taq-Man             PB                  UBC           213    399       205   305   557   278   Y
  rs1805010   Wang *et al.^51^*              2012   Asian       PCR-RFLP            PB                  HL            185    98        51    190   96    48    N
  rs1805010   Chu*et al.^32^*                2012   Asian       Taq-Man             PB                  RC            219    268       133   168   310   145   Y
  rs1805010   Ingram*et al.^33^*             2013   Mixed       Taq-Man             PB                  CRC           428    700       280   162   295   106   Y
  rs1805010   Liang *et al.^37^*             2017   Asian       PCR-LDR             HB                  RC            26     76        30    36    78    31    Y
  rs1805015   Schwartzbaum*et al.^11^*       2005   Caucasian   PCR-RFLP            PB                  Glioma        64     40        4     288   107   16    Y
  rs1805015   Ivansson*et al.^23^*           2007   Caucasian   Taq-Man             HB                  CC            871    379       44    176   94    16    Y
  rs1805015   Landi *et al.^24^*             2007   Caucasian   Taq-Man             HB                  CRC           201    73        7     362   164   6     N
  rs1805015   Wiemels*et al.^38^*            2007   Caucasian   PCR-RFLP            HB                  Glioma        274    99        13    341   113   16    Y
  rs1805015   Chu *et al.^9^*                2012   Asian       Taq-Man             PB                  UBC           673    141       2     951   182   7     Y
  rs1805015   Chu *et al.^32^*               2012   Asian       Taq-Man             PB                  RC            519    100       1     527   90    6     Y
  rs1805015   Li *et al.^12^*                2012   Asian       PCR                 PB                  Glioma        196    30        0     207   42    4     Y
  rs1805015   Ingram *et al.^33^*            2013   Mixed       Taq-Man             PB                  CRC           951    442       54    400   158   18    Y
  rs1805015   Shamran *et al.^41^*           2014   Caucasian   PCR-RFLP            PB                  Glioma        70     25        5     17    15    8     Y
  rs2057768   Crusius *et al.^42^*           2008   Caucasian   PCR                 PB                  GC            108    116       11    583   433   91    Y
  rs2057768   Wilkening*et al.^43^*          2008   Caucasian   Taq-Man             PB                  CRC           150    139       18    296   238   47    Y
  rs2057768   Burada *et al.^44^*            2012   Caucasian   Taq-Man             HB                  GC            53     40        12    144   85    13    Y

CRC: Colorectal cancer; GC: Gastric cancer; BC: Breast cancer; UBC: Bladder cancer; CC: Cervical cancer; PC: Pancreatic cancer; RC: Renal cancer; NPC: nasopharyngeal carcinoma; HL: Hodgkin\'s lymphoma; H-B: Hospital based; P-B: Population based; HWE: Hardy Weinberg Equilibrium

###### 

Results of meta-analysis for polymorphisms in and cancer susceptibility.

  Polymorphisms   Comparision   Subgroup    N    *P~H~*    *P~Z~*   *P~adjust~*   Random                Fixed
  --------------- ------------- ----------- ---- --------- -------- ------------- --------------------- --------------------
  **rs1801275**   B VS A        Overall     26   0.001     0.588    1.000         0.980(0.910-1.055)    1.007(0.963-1.053)
                  B VS A        Caucasian   14   0.089     0.983    1.000         0.998(0.909-1.095)    0.999(0.933-1.070)
                  B VS A        Asian       9    0.003     0.187    1.000         0.889(0.747-1.059)    0.939(0.857-1.029)
                  B VS A        Mixed       2    0.028     0.808    1.000         1.035(0.783-1.369)    1.054(0.929-1.194)
                  B VS A        PB          15   0.019     0.546    1.000         0.974(0.893-1.062)    1.010(0.956-1.067)
                  B VS A        HB          11   0.003     0.983    1.000         0.998(0.866-1.151)    1.000(0.925-1.082)
                  B VS A        CC          2    0.627     0.088    1.000         0.850(0.704-1.026)    0.849(0.704-1.025)
                  B VS A        RC          4    0.055     0.522    1.000         1.036(0.752-1.426)    1.055(0.895-1.243)
                  B VS A        GC          2    0.672     0.501    1.000         0.890(0.631-1.254)    0.733(0.281-1.914)
                  B VS A        BC          3    0.044     0.537    1.000         1.047(0.904-1.213)    1.060(0.981-1.144)
                  B VS A        Glioma      5    0.119     0.146    1.000         0.898(0.768-1.048)    0.925(0.832-1.028)
                  B VS A        CRC         3    0.002     0.497    1.000         0.874(0.591-1.291)    1.036(0.909-1.182)
                  B VS A        PC          2    0.015     0.462    1.000         1.340(0.615-2.922)    1.277(0.928-1.757)
                  B VS A        UBC         2    0.209     0.761    1.000         0.977(0.832-1.147)    0.980(0.863-1.114)
                  B VS A        PCR         9    0.03      0.613    1.000         0.971(0.866-1.089)    1.024(0.959-1.094)
                  B VS A        PCR-RFLP    7    0.013     0.338    1.000         1.111(0.895-1.379)    1.040(0.925-1.171)
                  B VS A        Taq-Man     8    0.222     0.969    1.000         0.992(0.908-1.084)    0.999(0.928-1.075)
                  B VS A        Y           22   0.002     0.658    1.000         0.981(0.901-1.068)    1.002(0.950-1.057)
                  B VS A        N           4    0.035     0.695    1.000         0.963(0.799-1.162)    1.018(0.937-1.106)
                  BA VS AA      Overall     26   0.003     0.181    1.000         0.941(0.860-1.029)    0.971(0.916-1.030)
                  BA VS AA      Caucasian   14   0.4       0.174    1.000         0.940(0.860-1.029)    0.942(0.865-1.027)
                  BA VS AA      Asian       9    0.002     0.362    1.000         0.907(0.735-1.119)    0.963(0.865-1.073)
                  BA VS AA      Mixed       2    0.008     0.86     1.000         0.963(0.636-1.458)    0.989(0.847-1.154)
                  BA VS AA      PB          15   0.009     0.142    1.000         0.914(0.812-1.031)    0.955(0.886-1.030)
                  BA VS AA      HB          11   0.05      0.751    1.000         0.977(0.847-1.127)    0.998(0.908-1.097)
                  BA VS AA      CC          2    0.623     0.699    1.000         0.953(0.746-1.217)    0.953(0.746-1.217)
                  BA VS AA      RC          4    0.143     0.127    1.000         1.146(0.831-1.579)    1.166(0.957-1.419)
                  BA VS AA      GC          2    0.754     0.734    1.000         0.935(0.631-1.384)    0.934(0.631-1.383)
                  BA VS AA      BC          3    0.02      0.927    1.000         1.011(0.801-1.275)    1.019(0.906-1.145)
                  BA VS AA      Glioma      5    0.047     0.297    1.000         0.892(0.719-1.106)    0.942(0.829-1.070)
                  BA VS AA      CRC         3    0.001     0.378    1.000         0.801(0.490-1.312)    0.990(0.841-1.165)
                  BA VS AA      PC          2    0.478     0.12     1.000         0.713(0.462-1.101)    0.710(0.461-1.093)
                  BA VS AA      UBC         2    0.08      0.242    1.000         0.899(0.684-1.180)    0.912(0.782-1.064)
                  BA VS AA      PCR         9    0.092     0.856    1.000         0.973(0.852-1.110)    1.009(0.919-1.107)
                  BA VS AA      PCR-RFLP    7    0.071     0.127    1.000         0.889(0.703-1.124)    0.891(0.768-1.034)
                  BA VS AA      Taq-Man     8    0.145     0.746    1.000         0.978(0.868-1.101)    0.985(0.899-1.079)
                  BA VS AA      Y           22   0.022     0.378    1.000         0.959(0.873-1.053)    0.985(0.923-1.052)
                  BA VS AA      N           4    0.009     0.258    1.000         0.838(0.616-1.139)    0.918(0.803-1.048)
                  BB VS AA      Overall     26   0.046     0.233    1.000         1.110(0.935-1.319)    1.127(1.006-1.261)
                  BB VS AA      Caucasian   14   0.019     0.276    1.000         1.172(0.881-1.561)    1.145(0.951-1.377)
                  BB VS AA      Asian       9    0.317     0.527    1.000         0.903(0.634-1.285)    0.907(0.672-1.226)
                  BB VS AA      Mixed       2    0.656     0.114    1.000         1.341(0.928-1.938)    1.345(0.931-1.941)
                  BB VS AA      PB          11   0.336     0.048    1.000         1.131(0.966-1.323)    1.138(1.001-1.295)
                  BB VS AA      HB          15   0.014     0.485    1.000         1.158(0.767-1.748)    1.088(0.860-1.377)
                  BB VS AA      CC          2    0.638     0.022    0.440         0.584(0.366-0.933)    0.581(0.364-0.925)
                  BB VS AA      RC          4    0.254     0.657    1.000         1.299(0.629-2.684)    1.123(0.673-1.873)
                  BB VS AA      GC          2    0.96      0.457    1.000         0.606(0.161-2.275)    0.605(0.161-2.271)
                  BB VS AA      BC          3    0.524     0.043    0.860         1.180(1.005-1.386)    1.181(1.006-1.386)
                  BB VS AA      Glioma      5    0.579     0.212    1.000         0.819(0.590-1.136)    0.812(0.586-1.126)
                  BB VS AA      CRC         3    0.466     0.259    1.000         1.231(0.842-1.798)    1.240(0.853-1.803)
                  BB VS AA      PC          2    0.016     0.239    1.000         3.333(0.449-24.745)   3.452(1.564-7.617)
                  BB VS AA      UBC         2    0.975     0.315    1.000         1.222(0.827-1.807)    1.222(0.827-1.807)
                  BB VS AA      PCR         9    0.225     0.212    1.000         1.039(0.815-1.324)    1.100(0.947-1.277)
                  BB VS AA      PCR-RFLP    7    0.021     0.052    1.000         1.765(0.995-3.130)    1.551(1.124-2.140)
                  BB VS AA      Taq-Man     8    0.409     0.747    1.000         1.022(0.826-1.263)    1.035(0.840-1.275)
                  BB VS AA      Y           22   0.027     0.516    1.000         1.076(0.862-1.343)    1.092(0.936-1.273)
                  BB VS AA      N           4    0.504     0.066    1.000         1.173(0.993-1.386)    1.169(0.990-1.382)
                  BA+BB VS AA   Overall     26   0.003     0.382    1.000         0.963(0.884-1.048)    0.990(0.936-1.047)
                  BA+BB VS AA   Caucasian   14   0.524     0.427    1.000         0.968(0.891-1.050)    0.967(0.891-1.050)
                  BA+BB VS AA   Asian       9    0.001     0.364    1.000         0.908(0.736-1.119)    0.958(0.863-1.063)
                  BA+BB VS AA   Mixed       2    0.01      0.993    1.000         0.998(0.676-1.474)    1.023(0.881-1.187)
                  BA+BB VS AA   PB          11   0.008     0.249    1.000         0.935(0.835-1.048)    0.980(0.913-1.052)
                  BA+BB VS AA   HB          15   0.052     0.877    1.000         1.001(0.873-1.148)    1.007(0.920-1.103)
                  BA+BB VS AA   CC          2    0.611     0.308    1.000         0.887(0.703-1.118)    0.886(0.703-1.118)
                  BA+BB VS AA   RC          4    0.136     0.115    1.000         1.171(0.857-1.599)    1.165(0.964-1.409)
                  BA+BB VS AA   GC          2    0.705     0.611    1.000         0.906(0.617-1.330)    0.905(0.616-1.329)
                  BA+BB VS AA   BC          3    0.017     0.746    1.000         1.037(0.833-1.292)    1.051(0.943-1.171)
                  BA+BB VS AA   Glioma      5    0.057     0.222    1.000         0.881(0.719-1.078)    0.926(0.819-1.047)
                  BA+BB VS AA   CRC         3    0.001     0.428    1.000         0.822(0.506-1.334)    1.014(0.867-1.185)
                  BA+BB VS AA   PC          2    0.341     0.893    1.000         0.974(0.659-1.438)    0.974(0.659-1.437)
                  BA+BB VS AA   UBC         2    0.107     0.414    1.000         0.929(0.729-1.183)    0.940(0.810-1.090)
                  BA+BB VS AA   PCR         9    0.038     0.61     1.000         0.965(0.839-1.108)    1.018(0.932-1.111)
                  BA+BB VS AA   PCR-RFLP    7    0.116     0.557    1.000         0.987(0.804-1.212)    0.959(0.832-1.104)
                  BA+BB VS AA   Taq-Man     8    0.165     0.84     1.000         0.983(0.880-1.099)    0.991(0.908-1.081)
                  BA+BB VS AA   Y           22   0.019     0.583    1.000         0.975(0.891-1.067)    0.997(0.936-1.062)
                  BA+BB VS AA   N           4    0.009     0.393    1.000         0.883(0.664-1.175)    0.963(0.852-1.088)
                  BB VS BA+AA   Overall     26   0.026     0.183    1.000         1.124(0.946-1.335)    1.094(0.991-1.207)
                  BB VS BA+AA   Caucasian   14   0.007     0.185    1.000         1.226(0.908-1.655)    1.175(0.979-1.411)
                  BB VS BA+AA   Asian       9    0.393     0.545    1.000         0.911(0.661-1.257)    0.912(0.676-1.230)
                  BB VS BA+AA   Mixed       2    0.959     0.113    1.000         1.342(0.932-1.932)    1.342(0.933-1.932)
                  BB VS BA+AA   PB          11   0.297     0.111    1.000         1.116(0.956-1.302)    1.093(0.980-1.218)
                  BB VS BA+AA   HB          15   0.007     0.419    1.000         1.193(0.778-1.830)    1.101(0.873-1.390)
                  BB VS BA+AA   CC          2    0.695     0.024    0.480         0.593(0.375-0.938)    0.590(0.374-0.931)
                  BB VS BA+AA   RC          4    0.268     0.727    1.000         1.264(0.626-2.554)    1.095(0.659-1.820)
                  BB VS BA+AA   GC          2    0.988     0.476    1.000         0.619(0.166-2.315)    0.619(0.166-2.314)
                  BB VS BA+AA   BC          3    0.414     0.168    1.000         1.093(0.963-1.240)    1.093(0.963-1.240)
                  BB VS BA+AA   Glioma      5    0.594     0.22     1.000         0.823(0.595-1.139)    0.817(0.591-1.129)
                  BB VS BA+AA   CRC         3    0.71      0.282    1.000         1.221(0.839-1.776)    1.226(0.846-1.778)
                  BB VS BA+AA   PC          2    0.01      0.218    1.000         3.776(0.456-31.263)   3.895(1.787-8.491)
                  BB VS BA+AA   UBC         2    0.833     0.227    1.000         1.270(0.861-1.871)    1.270(0.862-1.871)
                  BB VS BA+AA   PCR         9    0.325     0.452    1.000         1.030(0.850-1.248)    1.047(0.928-1.182)
                  BB VS BA+AA   PCR-RFLP    7    0.01      0.035    1.000         1.910(1.047-3.483)    1.648(1.201-2.261)
                  BB VS BA+AA   Taq-Man     8    0.401     0.7      1.000         1.029(0.833-1.271)    1.041(0.847-1.281)
                  BB VS BA+AA   Y           22   0.019     0.422    1.000         1.096(0.876-1.372)    1.101(0.946-1.281)
                  BB VS BA+AA   N           4    0.271     0.196    1.000         1.179(0.908-1.530)    1.089(0.957-1.240)
  **rs1805010**   B VS A        Overall     15   0.002     0.468    1.000         1.034(0.944-1.132)    1.012(0.959-1.068)
                  B VS A        Asian       7    0.051     0.609    1.000         0.998(0.883-1.126)    0.980(0.908-1.059)
                  B VS A        Caucasian   7    0.004     0.259    1.000         1.107(0.928-1.322)    1.068(0.977-1.168)
                  B VS A        PCR-RFLP    5    0.078     0.251    1.000         1.109(0.926-1.328)    1.071(0.953-1.203)
                  B VS A        PCR         3    0.885     0.139    1.000         0.903(0.788-1.034)    0.903(0.788-1.034)
                  B VS A        Taq-Man     6    0.001     0.498    1.000         1.055(0.903-1.234)    1.018(0.950-1.091)
                  B VS A        HB          8    0.025     0.133    1.000         1.114(0.968-1.282)    1.103(1.011-1.203)
                  B VS A        PB          7    0.058     0.253    1.000         0.964(0.867-1.071)    0.961(0.898-1.029)
                  B VS A        RC          4    0.001     0.358    1.000         1.180(0.829-1.678)    0.974(0.859-1.105)
                  B VS A        GC          4    0.083     0.434    1.000         0.987(0.793-1.229)    0.949(0.831-1.083)
                  B VS A        CRC         2    0.758     0.989    1.000         1.001(0.892-1.123)    1.001(0.892-1.123)
                  B VS A        Y           13   0.005     0.704    1.000         1.018(0.929-1.115)    1.005(0.951-1.062)
                  B VS A        N           2    0.033     0.329    1.000         1.493(0.667-3.343)    1.149(0.919-1.436)
                  BB VS AA      Overall     15   0.004     0.521    1.000         1.061(0.885-1.271)    1.024(0.919-1.142)
                  BB VS AA      Asian       7    0.108     0.573    1.000         0.976(0.781-1.220)    0.957(0.821-1.116)
                  BB VS AA      Caucasian   7    0.003     0.282    1.000         1.227(0.845-1.780)    1.140(0.949-1.369)
                  BB VS AA      PCR-RFLP    5    0.069     0.363    1.000         1.192(0.820-1.733)    1.115(0.882-1.411)
                  BB VS AA      PCR         3    0.931     0.089    1.000         0.782(0.589-1.039)    0.782(0.589-1.038)
                  BB VS AA      Taq-Man     6    0.002     0.433    1.000         1.127(0.836-1.520)    1.051(0.915-1.208)
                  BB VS AA      HB          8    0.027     0.172    1.000         1.226(0.915-1.643)    1.210(1.009-1.451)
                  BB VS AA      PB          7    0.068     0.315    1.000         0.933(0.758-1.148)    0.933(0.814-1.069)
                  BB VS AA      RC          4    0.003     0.324    1.000         1.407(0.714-2.773)    0.966(0.752-1.241)
                  BB VS AA      GC          4    0.124     0.26     1.000         0.902(0.592-1.376)    0.852(0.645-1.126)
                  BB VS AA      CRC         2    0.844     0.894    1.000         1.016(0.801-1.289)    1.016(0.801-1.289)
                  BB VS AA      Y           13   0.006     0.734    1.000         1.033(0.857-1.244)    1.009(0.902-1.130)
                  BB VS AA      N           2    0.062     0.286    1.000         1.848(0.498-6.859)    1.255(0.827-1.904)
                  BA VS AA      Overall     15   0.061     0.987    1.000         1.019(0.904-1.148)    1.001(0.917-1.092)
                  BA VS AA      Asian       7    0.025     0.838    1.000         1.022(0.828-1.262)    0.971(0.856-1.100)
                  BA VS AA      Caucasian   7    0.413     0.25     1.000         1.087(0.940-1.256)    1.088(0.943-1.255)
                  BA VS AA      PCR-RFLP    5    0.384     0.343    1.000         1.090(0.907-1.311)    1.090(0.912-1.303)
                  BA VS AA      PCR         3    0.339     0.678    1.000         1.043(0.824-1.321)    1.049(0.838-1.312)
                  BA VS AA      Taq-Man     6    0.018     0.74     1.000         0.966(0.788-1.184)    0.945(0.844-1.058)
                  BA VS AA      HB          8    0.637     0.049    0.980         1.150(0.999-1.322)    1.151(1.001-1.323)
                  BA VS AA      PB          7    0.073     0.123    1.000         0.913(0.773-1.078)    0.916(0.820-1.024)
                  BA VS AA      RC          4    0.004     0.976    1.000         0.992(0.583-1.688)    0.855(0.697-1.050)
                  BA VS AA      GC          4    0.506     0.232    1.000         1.136(0.918-1.407)    1.139(0.920-1.409)
                  BA VS AA      CRC         2    0.447     0.541    1.000         0.943(0.782-1.138)    0.943(0.782-1.137)
                  BA VS AA      Y           13   0.057     0.872    1.000         1.008(0.889-1.143)    0.993(0.907-1.086)
                  BA VS AA      N           2    0.162     0.509    1.000         1.381(0.575-3.316)    1.119(0.801-1.564)
                  BA+BB VS AA   Overall     15   0.018     0.576    1.000         1.036(0.916-1.172)    1.010(0.931-1.096)
                  BA+BB VS AA   Asian       7    0.013     0.862    1.000         1.019(0.828-1.254)    0.969(0.863-1.090)
                  BA+BB VS AA   Caucasian   7    0.208     0.145    1.000         1.103(0.930-1.308)    1.106(0.966-1.267)
                  BA+BB VS AA   PCR-RFLP    5    0.395     0.246    1.000         1.102(0.932-1.303)    1.103(0.935-1.300)
                  BA+BB VS AA   PCR         3    0.482     0.74     1.000         0.964(0.778-1.195)    0.965(0.779-1.194)
                  BA+BB VS AA   Taq-Man     6    0.002     0.89     1.000         1.016(0.809-1.277)    0.975(0.876-1.085)
                  BA+BB VS AA   HB          8    0.21      0.023    0.560         1.173(0.997-1.381)    1.167(1.022-1.332)
                  BA+BB VS AA   PB          7    0.105     0.139    1.000         0.926(0.800-1.073)    0.925(0.833-1.026)
                  BA+BB VS AA   RC          4    0.002     0.641    1.000         1.133(0.670-1.918)    0.897(0.741-1.087)
                  BA+BB VS AA   GC          4    0.259     0.609    1.000         1.059(0.825-1.359)    1.054(0.861-1.290)
                  BA+BB VS AA   CRC         2    0.513     0.677    1.000         0.963(0.806-1.150)    0.963(0.806-1.150)
                  BA+BB VS AA   Y           13   0.026     0.761    1.000         1.020(0.899-1.157)    0.999(0.917-1.088)
                  BA+BB VS AA   N           2    0.067     0.347    1.000         1.644(0.536-5.038)    1.152(0.858-1.545)
                  BB VS BA+AA   Overall     15   0.02      0.641    1.000         1.035(0.897-1.194)    1.025(0.933-1.126)
                  BB VS BA+AA   Asian       7    0.662     0.773    1.000         0.981(0.859-1.119)    0.981(0.860-1.119)
                  BB VS BA+AA   Caucasian   7    0.001     0.356    1.000         1.174(0.835-1.651)    1.073(0.915-1.257)
                  BB VS BA+AA   PCR-RFLP    5    0.04      0.464    1.000         1.149(0.793-1.664)    1.068(0.862-1.324)
                  BB VS BA+AA   PCR         3    0.738     0.03     0.6           0.770(0.605-0.979)    0.767(0.604-0.974)
                  BB VS BA+AA   Taq-Man     6    0.077     0.169    1.000         1.114(0.927-1.340)    1.087(0.965-1.225)
                  BB VS BA+AA   HB          8    0.078     0.209    1.000         1.100(0.877-1.380)    1.106(0.945-1.295)
                  BB VS BA+AA   PB          7    0.043     0.867    1.000         0.984(0.813-1.191)    0.982(0.874-1.104)
                  BB VS BA+AA   RC          4    0.027     0.273    1.000         1.309(0.809-2.119)    1.063(0.856-1.321)
                  BB VS BA+AA   GC          4    0.191     0.048    0.960         0.819(0.592-1.133)    0.785(0.617-0.998)
                  BB VS BA+AA   CRC         2    0.834     0.613    1.000         1.054(0.858-1.295)    1.054(0.859-1.295)
                  BB VS BA+AA   Y           13   0.018     0.823    1.000         1.017(0.875-1.183)    1.015(0.922-1.118)
                  BB VS BA+AA   N           2    0.176     0.375    1.000         1.366(0.668-2.793)    1.196(0.805-1.776)
  **rs1805015**   B VS A        Overall     9    \<0.001   0.408    1.000         0.928(0.777-1.108)    0.981(0.897-1.072)
                  B VS A        Caucasian   5    0.001     0.353    1.000         0.863(0.633-1.177)    0.903(0.792-1.031)
                  B VS A        Asian       3    0.202     0.689    1.000         0.943(0.754-1.179)    0.967(0.819-1.141)
                  B VS A        PCR-RFLP    3    \<0.001   0.576    1.000         0.831(0.435-1.589)    1.002(0.820-1.224)
                  B VS A        Taq-Man     5    0.099     0.928    1.000         0.980(0.847-1.134)    0.995(0.899-1.102)
                  B VS A        PB          6    \<0.001   0.528    1.000         0.918(0.703-1.198)    1.034(0.923-1.157)
                  B VS A        HB          3    0.207     0.15     1.000         0.903(0.752-1.085)    0.899(0.777-1.039)
                  B VS A        Glioma      4    \<0.001   0.364    1.000         0.788(0.472-1.317)    0.936(0.778-1.125)
                  B VS A        CRC         2    0.183     0.288    1.000         1.063(0.856-1.318)    1.085(0.933-1.261)
                  B VS A        Y           8    \<0.001   0.436    1.000         0.923(0.755-1.129)    0.988(0.899-1.085)
                  BB VS AA      Overall     9    0.014     0.172    1.000         0.688(0.403-1.176)    0.788(0.589-1.056)
                  BB VS AA      Caucasian   5    0.019     0.407    1.000         0.743(0.368-1.501)    0.745(0.507-1.093)
                  BB VS AA      Asian       3    0.686     0.014    0.280         0.256(0.080-0.818)    0.240(0.076-0.752)
                  BB VS AA      PCR-RFLP    3    0.024     0.372    1.000         0.593(0.189-1.867)    0.714(0.410-1.243)
                  BB VS AA      Taq-Man     5    0.047     0.527    1.000         0.807(0.415-1.570)    0.867(0.610-1.234)
                  BB VS AA      PB          6    0.013     0.098    1.000         0.461(0.184-1.152)    0.741(0.500-1.098)
                  BB VS AA      HB          3    0.093     0.468    1.000         0.942(0.467-1.900)    0.851(0.549-1.317)
                  BB VS AA      Glioma      4    0.031     0.213    1.000         0.503(0.170-1.484)    0.640(0.374-1.095)
                  BB VS AA      CRC         2    0.417     0.194    1.000         1.395(0.855-2.276)    1.386(0.847-2.270)
                  BB VS AA      Y           8    0.025     0.072    1.000         0.602(0.346-1.046)    0.731(0.540-0.989)
                  BA VS AA      Overall     9    0.021     0.968    1.000         1.003(0.849-1.185)    1.028(0.926-1.141)
                  BA VS AA      Caucasian   5    0.011     0.651    1.000         0.931(0.682-1.271)    0.933(0.795-1.096)
                  BA VS AA      Asian       3    0.378     0.552    1.000         1.056(0.884-1.262)    1.055(0.884-1.261)
                  BA VS AA      PCR-RFLP    3    0.012     0.992    1.000         1.003(0.551-1.824)    1.132(0.885-1.447)
                  BA VS AA      Taq-Man     5    0.134     0.706    1.000         1.007(0.859-1.181)    1.023(0.909-1.151)
                  BA VS AA      PB          6    0.044     0.522    1.000         1.074(0.863-1.338)    1.113(0.978-1.267)
                  BA VS AA      HB          3    0.301     0.186    1.000         0.889(0.734-1.078)    0.889(0.746-1.059)
                  BA VS AA      Glioma      4    0.012     0.814    1.000         0.946(0.595-1.504)    1.046(0.839-1.305)
                  BA VS AA      CRC         2    0.054     0.622    1.000         0.991(0.682-1.440)    1.046(0.875-1.250)
                  BA VS AA      Y           8    0.03      0.704    1.000         1.035(0.868-1.234)    1.058(0.948-1.182)
                  BA+BB VS AA   Overall     9    0.003     0.683    1.000         0.962(0.801-1.157)    1.004(0.908-1.110)
                  BA+BB VS AA   Caucasian   5    0.002     0.477    1.000         0.885(0.632-1.240)    0.911(0.781-1.062)
                  BA+BB VS AA   Asian       3    0.272     0.902    1.000         0.998(0.809-1.231)    1.011(0.848-1.205)
                  BA+BB VS AA   PCR-RFLP    3    0.001     0.738    1.000         0.889(0.446-1.773)    1.069(0.847-1.351)
                  BA+BB VS AA   Taq-Man     5    0.109     0.877    1.000         0.992(0.844-1.165)    1.009(0.900-1.132)
                  BA+BB VS AA   PB          6    0.004     0.96     1.000         0.993(0.765-1.291)    1.078(0.950-1.222)
                  BA+BB VS AA   HB          3    0.258     0.154    1.000         0.886(0.728-1.079)    0.885(0.748-1.047)
                  BA+BB VS AA   Glioma      4    0.001     0.535    1.000         0.845(0.496-1.440)    0.987(0.799-1.219)
                  BA+BB VS AA   CRC         2    0.083     0.433    1.000         1.025(0.740-1.420)    1.072(0.902-1.274)
                  BA+BB VS AA   Y           8    0.002     0.814    1.000         0.976(0.796-1.197)    1.024(0.920-1.139)
                  BB VS BA+AA   Overall     9    0.039     0.18     1.000         0.717(0.441-1.167)    0.788(0.590-1.052)
                  BB VS BA+AA   Caucasian   5    0.049     0.414    1.000         0.772(0.415-1.437)    0.764(0.523-1.115)
                  BB VS BA+AA   Asian       3    0.699     0.014    0.280         0.254(0.080-0.812)    0.239(0.076-0.749)
                  BB VS BA+AA   PCR-RFLP    3    0.08      0.221    1.000         0.625(0.249-1.571)    0.710(0.411-1.228)
                  BB VS BA+AA   Taq-Man     5    0.058     0.425    1.000         0.823(0.433-1.566)    0.867(0.611-1.231)
                  BB VS BA+AA   PB          6    0.041     0.086    1.000         0.493(0.220-1.105)    0.723(0.489-1.068)
                  BB VS BA+AA   HB          3    0.101     0.545    1.000         0.970(0.489-1.922)    0.875(0.567-1.349)
                  BB VS BA+AA   Glioma      4    0.094     0.099    1.000         0.549(0.225-1.341)    0.640(0.376-1.088)
                  BB VS BA+AA   CRC         2    0.32      0.234    1.000         1.357(0.834-2.208)    1.347(0.825-2.202)
                  BB VS BA+AA   Y           8    0.081     0.038    0.760         0.639(0.395-1.033)    0.727(0.539-0.982)
  **rs2057768**   B VS A        Overall     3    0.191     0.218    1.000         1.115(0.923-1.348)    1.093(0.949-1.260)
                  B VS A        Taq-Man     2    0.07      0.305    1.000         1.178(0.806-1.721)    1.102(0.915-1.327)
                  B VS A        PB          2    0.606     0.644    1.000         1.037(0.889-1.210)    1.037(0.889-1.210)
                  B VS A        GC          2    0.152     0.095    1.000         1.218(0.907-1.638)    1.173(0.973-1.414)
                  BB VS AA      Overall     3    0.032     0.96     1.000         1.019(0.488-2.129)    0.898(0.616-1.307)
                  BB VS AA      Taq-Man     2    0.022     0.642    1.000         1.321(0.408-4.274)    1.078(0.676-1.717)
                  BB VS AA      PB          2    0.742     0.117    1.000         0.709(0.459-1.095)    0.707(0.458-1.090)
                  BB VS AA      GC          2    0.013     0.745    1.000         1.245(0.331-4.678)    1.024(0.625-1.678)
                  BA VS AA      Overall     3    0.552     0.009    0.180         1.288(1.067-1.555)    1.288(1.067-1.554)
                  BA VS AA      Taq-Man     2    0.72      0.183    1.000         1.183(0.924-1.516)    1.183(0.924-1.516)
                  BA VS AA      PB          2    0.276     0.015    0.300         1.290(1.032-1.611)    1.289(1.051-1.581)
                  BA VS AA      GC          2    0.672     0.008    0.160         1.401(1.091-1.798)    1.401(1.091-1.798)
                  BA+BB VS AA   Overall     3    0.495     0.028    0.560         1.226(1.023-1.470)    1.226(1.023-1.470)
                  BA+BB VS AA   Taq-Man     2    0.303     0.191    1.000         1.176(0.918-1.507)    1.171(0.924-1.484)
                  BA+BB VS AA   PB          2    0.358     0.084    1.000         1.190(0.977-1.450)    1.190(0.977-1.450)
                  BA+BB VS AA   GC          2    0.725     0.016    0.320         1.343(1.056-1.709)    1.343(1.056-1.709)
                  BB VS BA+AA   Overall     3    0.021     0.82     1.000         0.916(0.429-1.955)    0.797(0.553-1.148)
                  BB VS BA+AA   Taq-Man     2    0.021     0.734    1.000         1.219(0.389-3.820)    0.998(0.635-1.569)
                  BB VS BA+AA   PB          2    0.557     0.031    0.610         0.634(0.415-0.967)    0.628(0.412-0.957)
                  BB VS BA+AA   GC          2    0.007     0.904    1.000         1.090(0.268-4.429)    0.870(0.539-1.403)

*P~H~*: P value of Q test for heterogeneity test; *P~Z~*: means statistically significant (*P* \< 0.05); *P~Adjust~*: Multiple testing *P* value according to Bonferroni Correction; CRC: Colorectal cancer; GC: Gastric cancer; BC: Breast cancer; UBC: Bladder cancer; CC: Cervical cancer; PC: Pancreatic cancer; RC: Renal cancer; NPC: nasopharyngeal carcinoma; HL: Hodgkin\'s lymphoma; H-B: Hospital based; P-B: Population based; HWE: Hardy Weinberg Equilibrium; *P~adjust~* value less than 0.05\*(4 polymorphisms\* 5 models) was considered as statistically significant, which was marked with bold font in the table). Note: Heterogeneity was considered to be significant when the P-value was less than 0.1. If there was no significant heterogeneity, a fixed effect model (Der-Simonian Laird) was used to evaluate the point estimates and 95% CI; otherwise, a random effects model (Der-Simonian Laird) was used. And the *Pz* was calculated based on the actual model adopted.
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